Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1563–1568. doi: 10.1038/bjc.1996.295

A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.

L E James 1, N H Gower 1, R M Rudd 1, S G Spiro 1, P G Harper 1, C W Trask 1, M Partridge 1, M C Ruiz de Elvira 1, R L Souhami 1
PMCID: PMC2074560  PMID: 8664131

Abstract

We report the results of a randomised trial in extensive small-cell lung cancer (SCLC) of a novel approach to palliative chemotherapy. A widely used 3 weekly regimen was compared with the same drugs given at half the dose but twice the frequency with the same intended overall dose intensity (DI). A total of 167 patients defined as having extensive SCLC with adverse prognostic features were randomised to receive either a 3 weekly regimen of cisplatin 60 mg m-2 i.v. on day 1 and etoposide 120 mg m-2 i.v. on day 1 and 100 mg b.d. orally on days 2 and 3 alternating with cyclophosphamide 600 mg m-2 i.v., doxorubicin 50 mg m-2 i.v. and vincristine 2 mg i.v. all on day 1 for a maximum of six courses (3 weekly); or treatment with the same drugs but with each course consisting of half the 3 weekly dose given every 10 or 11 days for a maximum of 12 courses. In the 10/11 day regimen overall response rate was 58.9% (95% CI, 47.9-69.2%) with 12.8% complete responses (CR). For the 3 weekly treatment the overall response rate was 44.9% (95% CI, 35.0-55.5%) with 10.1% CR. Median survival was similar in the two arms at 6.4 months (95% CI, 4.9-7.3 months) and 5.8 months (95% CI, 4.0-6.6 months) respectively. Survival at 1 year was 9.9% (95% CI, 5.0-18.5%) and 8.9% (95% CI, 4.6-16.6%). The 95% CI for the difference in survival at 1 year is -7.09% to +9.09%. Haematological toxicity and treatment delays owing to infection were more frequent with the 10/11 day regimen but other toxicities were equal in both arms. Other aspects of quality of life were measured in a small representative cohort of patients using a daily diary card (DDC). There was a trend of improved quality of life on the 10/11 day arm, but there was little difference between the two treatments. The trial shows that a low-dose/high-frequency regimen with the same DI as conventionally scheduled chemotherapy gives similar response rates and survival. This and other modifications of the schedule may offer new approaches to palliative treatment of advanced cancer. However, in this trial there was no significant benefit in toxicity or other aspects of quality of life.

Full text

PDF
1563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byrne A., Carney D. N. Small cell lung cancer in the elderly. Semin Oncol. 1994 Jun;21(3 Suppl 6):43–48. [PubMed] [Google Scholar]
  2. Carney D. N., Grogan L., Smit E. F., Harford P., Berendsen H. H., Postmus P. E. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol. 1990 Feb;17(1 Suppl 2):49–53. [PubMed] [Google Scholar]
  3. Clark A., Fallowfield L. J. Quality of life measurements in patients with malignant disease: a review. J R Soc Med. 1986 Mar;79(3):165–169. doi: 10.1177/014107688607900311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Earl H. M., Rudd R. M., Spiro S. G., Ash C. M., James L. E., Law C. S., Tobias J. S., Harper P. G., Geddes D. M., Eraut D. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1991 Sep;64(3):566–572. doi: 10.1038/bjc.1991.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fayers P. M., Bleehen N. M., Girling D. J., Stephens R. J. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer. 1991 Aug;64(2):299–306. doi: 10.1038/bjc.1991.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feld R., Evans W. K., Coy P., Hodson I., MacDonald A. S., Osoba D., Payne D., Shelley W., Pater J. L. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987 Sep;5(9):1401–1409. doi: 10.1200/JCO.1987.5.9.1401. [DOI] [PubMed] [Google Scholar]
  7. Figueredo A. T., Hryniuk W. M., Strautmanis I., Frank G., Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985 Jan;3(1):54–64. doi: 10.1200/JCO.1985.3.1.54. [DOI] [PubMed] [Google Scholar]
  8. Geddes D. M., Dones L., Hill E., Law K., Harper P. G., Spiro S. G., Tobias J. S., Souhami R. L. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer. 1990 Apr;26(4):484–492. doi: 10.1016/0277-5379(90)90022-l. [DOI] [PubMed] [Google Scholar]
  9. Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121–141. [PubMed] [Google Scholar]
  10. Ihde D. C., Mulshine J. L., Kramer B. S., Steinberg S. M., Linnoila R. I., Gazdar A. F., Edison M., Phelps R. M., Lesar M., Phares J. C. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct;12(10):2022–2034. doi: 10.1200/JCO.1994.12.10.2022. [DOI] [PubMed] [Google Scholar]
  11. Klasa R. J., Murray N., Coldman A. J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991 Mar;9(3):499–508. doi: 10.1200/JCO.1991.9.3.499. [DOI] [PubMed] [Google Scholar]
  12. Miles D. W., Earl H. M., Souhami R. L., Harper P. G., Rudd R., Ash C. M., James L., Trask C. W., Tobias J. S., Spiro S. G. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol. 1991 Feb;9(2):280–285. doi: 10.1200/JCO.1991.9.2.280. [DOI] [PubMed] [Google Scholar]
  13. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rawson N. S., Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990 Apr;61(4):597–604. doi: 10.1038/bjc.1990.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sculier J. P., Paesmans M., Bureau G., Dabouis G., Libert P., Vandermoten G., Van Cutsem O., Berchier M. C., Ries F., Michel J. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol. 1993 Oct;11(10):1858–1865. doi: 10.1200/JCO.1993.11.10.1858. [DOI] [PubMed] [Google Scholar]
  16. Slevin M. L., Plant H., Lynch D., Drinkwater J., Gregory W. M. Who should measure quality of life, the doctor or the patient? Br J Cancer. 1988 Jan;57(1):109–112. doi: 10.1038/bjc.1988.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]
  18. Souhami R. L., Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990 Apr;61(4):584–589. doi: 10.1038/bjc.1990.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Souhami R. L., Rudd R., Ruiz de Elvira M. C., James L., Gower N., Harper P. G., Tobias J. S., Partridge M. R., Davison A. G., Trask C. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol. 1994 Sep;12(9):1806–1813. doi: 10.1200/JCO.1994.12.9.1806. [DOI] [PubMed] [Google Scholar]
  20. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES